The online home of Neurology Reviews

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Ponesimod reduces annualized relapse rate, compared with teriflunomide

Publish date:: September 12, 2019

Key clinical point: Ponesimod reduces the number of confirmed MS relapses, compared with teriflunomide.

Major finding: Annualized relapse rate was 30.5% lower with ponesimod, compared with teriflunomide.

Study details: A randomized, double-blind, superiority study of 1,133 patients with relapsing-remitting MS.

Disclosures: Actelion Pharmaceuticals sponsored the study.

Citation:

Kappos L et al. ECTRIMS 2019, Abstract 93.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Multiple Sclerosis

Long-term safety and efficacy of teriflunomide for relapsing MS,

Newer DMTs are more effective than injectable DMTs in pediatric MS,

Neutrophil granulocyte markers may distinguish between demyelinating diseases,

Bacteria may be associated with risk of MS relapse,

Women with MS may have increased subclinical disease activity during pregnancy,